Anti-Inflammatory drug could boost stroke recovery after clot removal
NCT ID NCT07449910
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding the anti-inflammatory drug baricitinib to standard clot-removal treatment helps people recover better after a severe stroke caused by a blocked artery in the front of the brain. About 750 adults will receive either baricitinib or a placebo for five days, and their level of disability will be measured three months later. The goal is to see if calming brain inflammation can reduce long-term disability.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Baricitinib (an anti-inflammatory drug)
- What this could lead to
- If it works, this could offer a new way to improve recovery and reduce disability after a major stroke by adding an anti-inflammatory drug to standard clot-removal treatment.
- What could go wrong
- This is an early-to-mid-stage trial (Phase 2/3) with 750 participants. The drug may not improve outcomes, and there are risks of infection or other side effects from baricitinib.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 750 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Mar 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age is 18 years old or above. 2. Diagnosed as anterior circulation large vessel occlusion stroke by CTA, MRA or DSA. 3. Randomized within 24h after the onset. 4. The NIHSS score is above 5 and the ASPECT score is above 3 points while receiving imaging examination; 5. The mTICI score after endovascular treatment (EVT) is above 2b. 6. informed consent. Exclusion Criteria: 1. Intracranial hemorrhage confirmed by CT or MRI. 2. mRS score\>2 for patients \<80 years, or mRS score\>1 for those ≥80 years before onset. 3. Pregnant or lactating women. 4. Allergic to contrast agents. 5. Allergic to baricitinib or having contraindications for using baricitinib. 6. Participating in other clinical studies. 7. Systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg, and unable to be controlled by oral antihypertensive drugs. 8. Genetic or acquired bleeding diathesis, lack of anticoagulant factors or having taken oral anticoagulants and INR \>1.7. 9. Hemoglobin value \<8g/L. 10. Recent history of using other JAK inhibitors or potent immunosuppressants, including but not limited to the combined use with potent immunosuppressive drugs such as azathioprine, tacrolimus, tofacitinib and fedratinib, etc. Tortuous arteries make the thrombectomy device unable to reach the target blood vessel. 11. Previous history of diagnosed viral hepatitis and tuberculosis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute anterior circulation large vessel occlusion stroke are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Recruiting
Hefei, Anhui, 230001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.